BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Opening Innovativeness: Moving Thoughts and Tasks - 2Volcanic eruption led to the Black Death, new research suggests
- 3Favored Vehicle for Seniors: Make Your Determination
- 4Getting through a Lifelong Change: Individual Examples of overcoming adversity
- 5Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- The best overlooked performances of 2025
- Cells have more mini ‘organs’ than researchers thought − unbound by membranes, these rogue organelles challenge biology’s fundamentals
- Monetary Wellness: Planning Tips for Independence from the rat race
- Vote In favor of Your Favored Keeping an eye on
- CRP Subsea secures contract for Vattenfall’s Nordlicht I cable systems
- Home Plan Tips for Seniors
- Pick Your Favored kind of sandwich
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
